<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315948</url>
  </required_header>
  <id_info>
    <org_study_id>C20-15</org_study_id>
    <secondary_id>101015736</secondary_id>
    <nct_id>NCT04315948</nct_id>
  </id_info>
  <brief_title>Trial of Treatments for COVID-19 in Hospitalized Adults</brief_title>
  <acronym>DisCoVeRy</acronym>
  <official_title>Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DisCoVeRy is a randomized controlled trial among adults (≥18-year-old) hospitalized for&#xD;
      COVID-19. This study is an adaptive, randomized, open or blinded, depending on the drug to be&#xD;
      evaluated, clinical trial to evaluate the safety and efficacy of possible therapeutic agents&#xD;
      in hospitalized adult patients diagnosed with COVID-19. The study is a multi-centre/country&#xD;
      trial that will be conducted in various sites in Europe with Inserm as sponsor. The study&#xD;
      will compare different investigational therapeutic agents to a control group managed with the&#xD;
      SoC including corticosteroids and anticoagulants. There will be interim monitoring to allow&#xD;
      early stopping for safety and to introduce new therapies as they become available. If one&#xD;
      therapy proves to be superior to others in the trial, this treatment may become part of the&#xD;
      SoC for comparison(s) with new experimental treatment(s).&#xD;
&#xD;
      In previous versions of the DisCoVeRy protocol, remdesivir, lopinavir/ritonavir with or&#xD;
      without interferon ß-1a and hydroxychloroquine were evaluated as potential treatments for&#xD;
      COVID-19. These treatments have been discontinued based on analyses review by both DSMC/DSMB,&#xD;
      the Solidarity Executive Group and the DisCoVeRy steering committee.&#xD;
&#xD;
      This version of the protocol, therefore, describes a randomized blinded placebo-controlled&#xD;
      trial among adults (≥18-year-old) hospitalized for COVID-19 that randomly allocates them (1:1&#xD;
      ratio) between 2 arms: SoC + placebo versus SoC + AZD7442.&#xD;
&#xD;
      Randomization will be stratified by region (according to the administrative definition in&#xD;
      each country), antigenic status (positive or negative) obtained from the result of a rapid&#xD;
      antigen test on nasopharyngeal swab performed at enrolment and vaccination initiation (yes or&#xD;
      no).&#xD;
&#xD;
      The primary analyses will be conducted on patients with antigen-positive results. A positive&#xD;
      antigenic test is evidence of high viral shedding consistent with a recently started or&#xD;
      uncontrolled infection. Overall, the number of antigen-negative patients will be at most 30%&#xD;
      of all included subjects. The number of patients with vaccination (partly or fully) will be&#xD;
      limited to 20% of all participants, split evenly between antigen positive and antigen&#xD;
      negative patients (i.e. vaccinated patients can make up at most 20% of antigene positive&#xD;
      patients and 20% of antigene negative patients). Sensitivity analyses will be performed in&#xD;
      all patients, stratified by antigenic status and vaccination initiation.&#xD;
&#xD;
      A global independent data and safety monitoring board (DSMB) monitors interim data to make&#xD;
      recommendations about early study closure or changes to conduct, including adding or removing&#xD;
      treatment arms. However, the current version of the protocol does not allow for efficacy or&#xD;
      futility analysis, and the ability to add trial arms will be limited by the study being&#xD;
      blinded and placebo-controlled during the investigation of AZD7442.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DisCoVeRy is a randomized controlled trial among adults (≥18-year-old) hospitalized for&#xD;
      COVID-19. This study is an adaptive, randomized, open or blinded, depending on the drug to be&#xD;
      evaluated, clinical trial to evaluate the safety and efficacy of possible therapeutic agents&#xD;
      in hospitalized adult patients diagnosed with COVID-19. The study is a multi-centre/country&#xD;
      trial that will be conducted in various sites in Europe with Inserm as sponsor. The study&#xD;
      will compare different investigational therapeutic agents to a control group managed with the&#xD;
      SoC including corticosteroids and anticoagulants. There will be interim monitoring to allow&#xD;
      early stopping for safety and to introduce new therapies as they become available. If one&#xD;
      therapy proves to be superior to others in the trial, this treatment may become part of the&#xD;
      SoC for comparison(s) with new experimental treatment(s).&#xD;
&#xD;
      In previous versions of the DisCoVeRy protocol, remdesivir, lopinavir/ritonavir with or&#xD;
      without interferon ß-1a and hydroxychloroquine were evaluated as potential treatments for&#xD;
      COVID-19. These treatments have been discontinued based on analyses review by both DSMC/DSMB,&#xD;
      the Solidarity Executive Group and the DisCoVeRy steering committee.&#xD;
&#xD;
      This version of the protocol, therefore, describes a randomized blinded placebo-controlled&#xD;
      trial among adults (≥18-year-old) hospitalized for COVID-19 that randomly allocates them (1:1&#xD;
      ratio) between 2 arms: SoC + placebo versus SoC + AZD7442.&#xD;
&#xD;
      Randomization will be stratified by region (according to the administrative definition in&#xD;
      each country), antigenic status (positive or negative) obtained from the result of a rapid&#xD;
      antigen test on nasopharyngeal swab performed at enrolment and vaccination initiation (yes if&#xD;
      at least one injection of any vaccine against SARS-CoV-2 was reveived prior to enrolment&#xD;
      whatever the delay or no).&#xD;
&#xD;
      The primary analyses will be conducted on patients with antigen-positive results. A positive&#xD;
      antigenic test is evidence of high viral shedding consistent with a recently started or&#xD;
      uncontrolled infection. Overall, the number of antigen-negative patients will be at most 30%&#xD;
      of all included subjects. The number of patients with vaccination (partly or fully) will be&#xD;
      limited to 20% of all participants, split evenly between antigen positive and antigen&#xD;
      negative patients (i.e. vaccinated patients can make up at most 20% of antigene positive&#xD;
      patients and 20% of antigene negative patients). Sensitivity analyses will be performed in&#xD;
      all patients, stratified by antigenic status and vaccination initiation.&#xD;
&#xD;
      A global independent data and safety monitoring board (DSMB) monitors interim data to make&#xD;
      recommendations about early study closure or changes to conduct, including adding or removing&#xD;
      treatment arms. However, the current version of the protocol does not allow for efficacy or&#xD;
      futility analysis, and the ability to add trial arms will be limited by the study being&#xD;
      blinded and placebo-controlled during the investigation of AZD7442.&#xD;
&#xD;
      All subjects will undergo a series of efficacy and safety assessments, including laboratory&#xD;
      assays.&#xD;
&#xD;
      Subjects will be assessed at baseline, and at Days 3, 8 and 15 while hospitalized. Patients&#xD;
      will be contacted by phone at Day 15 for evaluation of the Primary Endpoint if they have been&#xD;
      discharged prior to Day 15-, and 14-days following hospital discharge for efficacy&#xD;
      assessment.&#xD;
&#xD;
      Further follow-up assessments will be organized at Days 29, 90, 180, 365 and 456.&#xD;
&#xD;
      If discharged from the hospital, days 29 and 90 assessments will be organized as outpatients'&#xD;
      consultations for all. For Days 180 and 365 assessments, a subset of 25% of patients enrolled&#xD;
      in centers with available resources and selected at Day 90 will be evaluated during a medical&#xD;
      consultation, while the other will be contacted by phone. For Day 456, all patients will be&#xD;
      contacted by phone.&#xD;
&#xD;
      Nasopharyngeal swabs (NP) or lower respiratory tract samples will be obtained at baseline&#xD;
      (Day 1 pre-treatment) and at Days 3, 8, 15 (while hospitalized) and 29 (while hospitalized&#xD;
      or, if discharged from the hospital, in the outpatient setting).&#xD;
&#xD;
      Blood samples will be obtained at baseline (Day 1 pre-treatment) and at Days 3, 8, 15 (while&#xD;
      hospitalized), at Days 29 and 90, and at Days 180 and 365 (for the subset of patients&#xD;
      evaluated during a medical consultation at these times).&#xD;
&#xD;
      Thoracic computed tomography (CT)-scan will be obtained at baseline, depending on the&#xD;
      centre's imagery capacities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>From March 22, 2020 to May 24, 2020, the study randomized participants 1:1:1:1:1 to standard of care alone (control) or with investigational product added.&#xD;
From May 24, 2020 to June 29, 2020, the study randomized participants 1:1:1:1 to standard of care alone (control) or with investigational product added.&#xD;
From June 29, 2020 to January 19,2021, the study randomized participants 1:1 to standard of care alone (control) or with investigational product added.&#xD;
Since April, 2021, the study will randomize participants 1:1 to standard of care with placebo (control) or standard of care with investigational product added.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>the treatment arm SOC + hydroxychloroquine has been ceased since May 24, 2020;&#xD;
the treatment arm SOC + lopinavir / Ritonavir and lopinavir / ritonavir + interferon ß-1a has been ceased since June 29, 2020&#xD;
the treatment arm SOC + remdesivir has been ceased since January 19, 2021&#xD;
the treatment arm SOC + AZD7442</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects reporting each severity rating on a 7-point ordinal scale</measure>
    <time_frame>Day 15</time_frame>
    <description>Not hospitalized, no limitations on activities&#xD;
Not hospitalized, limitation on activities;&#xD;
Hospitalized, not requiring supplemental oxygen;&#xD;
Hospitalized, requiring supplemental oxygen;&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO;&#xD;
Death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Status on an ordinal scale</measure>
    <time_frame>Days 29, 90, 180 and 365</time_frame>
    <description>Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Early Warning Score 2 (NEWS-2 score)</measure>
    <time_frame>Days 3, 8, 15, and 29</time_frame>
    <description>Change from baseline in NEWS-2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oxygenation free days in the first 28 days</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days in the first 28 days</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new mechanical ventilation use during the trial.</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for mechanical ventilation or death by Day 15</measure>
    <time_frame>Day 15</time_frame>
    <description>Proportion of patients with mechanical ventilation or death at day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>29 days</time_frame>
    <description>Time to hospital discharge (days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>In hospital, Days 29, 90, 180, 365, 456</time_frame>
    <description>Rate of mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of new hospitalization</measure>
    <time_frame>Days 90, 180 and 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of confirmed re-infection with SARS-CoV-2</measure>
    <time_frame>Days 90, 180 and 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of serious adverse events (SAEs)</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of Grade 1- 2 hypersensitivity- related and infusion related AEs until D29 visit</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of Grade 3 and 4 adverse events (AEs)</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of AEs of Special Interest</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent of subjects with SARS-CoV-2 detectable in nasopharyngeal sample</measure>
    <time_frame>Days 3, 5, 8, 11, 15, 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quantitative SARS-CoV-2 virus in nasopharyngeal sample</measure>
    <time_frame>Days 3, 5, 8, 11, 15, 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quantitative SARS-CoV-2 virus in blood</measure>
    <time_frame>Days 3, 8</time_frame>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">2416</enrollment>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Remdesivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remdesivir will be administered as a 200 mg intravenous loading dose on Day 1, followed by a 100 mg once-daily intravenous maintenance dose for the duration of the hospitalization up to a 10 days total course.&#xD;
n=475</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lopinavir/ritonavir (stopped on June 29, 2020)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.&#xD;
n=620</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lopinavir/ritonavir plus Interferon ß-1a (stopped on June 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.&#xD;
Interferon ß1a will be administered subcutaneously at the dose of 44 µg for a total of 3 doses in 6 days (day 1, day 3, day 6).&#xD;
n=620</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine (stopped on May 24, 2020)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine will be administered orally as a loading dose of 400 mg twice daily for one day followed by 400 mg once daily for 9 days. The loading dose of hydroxychloroquine through a nasogastric tube will be increased to 600 mg twice a day for one day, followed by a maintenance dose of 400 mg once a day for 9 days n=620</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care alone before March, 2021.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD7442</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the AZD7442 group will receive a total dose of 600 mg AZD7442 via a co-administered (300 mg AZD8895 and 300 mg AZD1061) single IV infusion on Day 1.&#xD;
n=620</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care with placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care with placebo since April, 2021 n=620</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.</description>
    <arm_group_label>Remdesivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the &quot;a&quot; logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL).</description>
    <arm_group_label>Lopinavir/ritonavir (stopped on June 29, 2020)</arm_group_label>
    <arm_group_label>Lopinavir/ritonavir plus Interferon ß-1a (stopped on June 29)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Beta-1A</intervention_name>
    <description>IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.</description>
    <arm_group_label>Lopinavir/ritonavir plus Interferon ß-1a (stopped on June 29)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).</description>
    <arm_group_label>Hydroxychloroquine (stopped on May 24, 2020)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>AZD7442</arm_group_label>
    <arm_group_label>Hydroxychloroquine (stopped on May 24, 2020)</arm_group_label>
    <arm_group_label>Lopinavir/ritonavir (stopped on June 29, 2020)</arm_group_label>
    <arm_group_label>Lopinavir/ritonavir plus Interferon ß-1a (stopped on June 29)</arm_group_label>
    <arm_group_label>Remdesivir</arm_group_label>
    <arm_group_label>Standard of care alone</arm_group_label>
    <arm_group_label>Standard of care with placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7442</intervention_name>
    <description>AZD7442 will be supplied as separate vials of AZD8895 and AZD1061 containing 150 mg colorless to slightly yellow, clear to opalescent solutions for injection.</description>
    <arm_group_label>AZD7442</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Since April, 2021, the placebo will be a 0.9% (w/v) NaCl solution for infusion also called saline. The placebo will be supplied as a single 10-mL, clear and colorless vial.</description>
    <arm_group_label>Standard of care with placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult ≥18 years of age at the time of enrolment&#xD;
&#xD;
          2. Hospitalized patients with any of the following criteria:&#xD;
&#xD;
               1. the presence of pulmonary rales/crackles on clinical exam OR&#xD;
&#xD;
               2. SpO2 ≤ 94% on room air OR&#xD;
&#xD;
               3. requirement of supplementary oxygen including high flow oxygen devices or&#xD;
                  non-invasive ventilation&#xD;
&#xD;
          3. A time between onset of symptoms and randomization of less than 11 days&#xD;
&#xD;
          4. A positive SARS-CoV-2 PCR performed on a NP swab within the 5 days preceding&#xD;
             randomization&#xD;
&#xD;
          5. The result of a rapid antigen test performed on a NP swab within the 6 hours preceding&#xD;
             randomization&#xD;
&#xD;
          6. Contraceptive use by men or women.&#xD;
&#xD;
               1. Male participants: Contraception for male participants is required; to avoid the&#xD;
                  transfer of any fluids, all male participants must use a condom from Day 1 and&#xD;
                  agree to continue for 90 days following administration of IMP.&#xD;
&#xD;
               2. Female participants: Women of child-bearing potential must agree to use&#xD;
                  contraception for 365 days following administration of IMP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refusal to participate expressed by patient or legally authorized representative&#xD;
&#xD;
          2. Need for invasive mechanical ventilation and/or ECMO at the time of enrolment&#xD;
&#xD;
          3. Spontaneous blood ALT/AST levels &gt; 5 times the upper limit of normal&#xD;
&#xD;
          4. Glomerular filtration rate (GFR) &lt; 15 mL/min or requiring maintenance dialysis&#xD;
&#xD;
          5. Pregnancy or breast-feeding&#xD;
&#xD;
          6. Anticipated transfer to another hospital, which is not a study site within 72 hours&#xD;
             following randomization&#xD;
&#xD;
          7. Known history of allergy or reaction to any component of the study drug formulation.&#xD;
&#xD;
          8. Previous hypersensitivity, infusion-related reaction, or severe adverse reaction&#xD;
             following administration of monoclonal or polyclonal antibodies.&#xD;
&#xD;
          9. Any prior receipt of investigational or licensed other mAb/biologic indicated for the&#xD;
             prevention of SARS-CoV-2 infection or COVID-19, and for those not vaccinated, expected&#xD;
             receipt of vaccine in the 30 days following hospital discharge, according to current&#xD;
             recommendation in each country.&#xD;
&#xD;
         10. Any medical condition which, in the judgment of the investigator, could interfere with&#xD;
             the interpretation of the trial results or that preludes to protocol adherence.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence Ader, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence Ader, MD</last_name>
    <phone>+33 (0)4 72 07 15 60</phone>
    <email>florence.ader@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène Espérou, MD</last_name>
    <phone>+33 1 44 23 60 70</phone>
    <email>helene.esperou@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael JOANNIDIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard GREIL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme - Cliniques universitaires de Bruxelles</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maya HITES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leila BELKHIR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoine ALTDORFER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Philippe LANOIX</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoann ZERBIB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Metz-Thionville</name>
      <address>
        <city>Ars-Laquenexy</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kevin BOUILLER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe NAVELLOU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Denis MALVY</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier GRUSON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU APHP Ambroise-Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth ROUVEIX-NORDON</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume GERI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Andrée Rosemon</name>
      <address>
        <city>Cayenne</city>
        <zip>97306</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier LESENS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand SOUWEINE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civil</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin MARTINOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henry LESSIRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - hôpital Henri-Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sébastien GALLIEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armand MEKONTSO DESSAP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Dijon-Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lionel PIROTH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierre QUENOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Martinique</name>
      <address>
        <city>Fort De France</city>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>André CABIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyrille CHABARTIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Bicêtre</name>
      <address>
        <city>Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stéphane JAUREGUIBERRY</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samy FIGUEIREDO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalo-Universitaire de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emma D'ANGLEJAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuel Faure</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Poissy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florence ADER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe RICHARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mont de Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <zip>40024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Flore LACASSIN-BELLER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent LE MOING</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kada KLOUCHE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier de la Région de Mulhouse Sud Alsace</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joy MOOTIEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier HINSCHBERGER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional et Universitaire de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François GOEHRINGER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien GIBOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François Raffi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Reignier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalo-Universitaire de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johan COURJEON</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean DELLAMONICA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claire ROGER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pierre SELLIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nathalie DE CASTRO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karine LACOMBE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hafid AIT TOUFELLA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Universitaire Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Paris Saint-Joseph et Marie Lannelongue</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fanny LANTERNIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP- Hôpital Européen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nathan Peiffer-Smadja</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François Timsit</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles PIALOUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>France CAZENAVE-ROBLOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Cornouaille</name>
      <address>
        <city>Quimper</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nadia SAIDANI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guilhem WATTECAMPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Firouze BANI-SADR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno MOURVILLIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François BENEZIT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves LE TULZO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital DELAFONTAINE</name>
      <address>
        <city>Saint-Denis</city>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées BEGIN</name>
      <address>
        <city>Saint-Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth BOTELHO-NEVERS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume THIERY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François DANION</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ferhat MEZIANI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guillaume MARTIN BLONDEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fanny BOUNES - VARDON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guillaume MARTIN BLONDEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Béatrice RIU-POULENC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adrien LEMAIGNEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis GAROT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Bretagne Atlantique</name>
      <address>
        <city>Vannes</city>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie GOUSSEFF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Bretagne Atlantique</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie GOUSSEFF</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agathe DELBOVE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Épagny</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Violaine TOLSMA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David BOUGON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <zip>L-1210</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thérèse STAUB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Robert Schuman</name>
      <address>
        <city>Luxembourg</city>
        <zip>L-2450</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marc BERNIA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akershus Unniversity Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olav Dalgard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lovisenberg Diaconal Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Simen Schive</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne Ma Dyrhol Riise</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Abrantes (CHMT)</name>
      <address>
        <city>Abrantes</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Cascais</name>
      <address>
        <city>Cascais</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHULN- Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário de São João, EPE</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Luxembourg</country>
    <country>Norway</country>
    <country>Portugal</country>
  </location_countries>
  <reference>
    <citation>Ader F; Discovery French Trial Management Team. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ Open. 2020 Sep 21;10(9):e041437. doi: 10.1136/bmjopen-2020-041437.</citation>
    <PMID>32958495</PMID>
  </reference>
  <results_reference>
    <citation>WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.</citation>
    <PMID>33264556</PMID>
  </results_reference>
  <results_reference>
    <citation>Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure FX, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouiller K, Navellou JC, Tolsma V, Cabié A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix JP, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard JC, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Lê MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy study group. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021 May 26. pii: S1198-743X(21)00259-7. doi: 10.1016/j.cmi.2021.05.020. [Epub ahead of print]</citation>
    <PMID>34048876</PMID>
  </results_reference>
  <results_reference>
    <citation>Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy Study Group. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021 Sep 14. pii: S1473-3099(21)00485-0. doi: 10.1016/S1473-3099(21)00485-0. [Epub ahead of print]</citation>
    <PMID>34534511</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Remdesivir</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol and statistical analysis plan will be available. Systematic individual patient data sharing is not intended, but all requests for the trial's data will be considered by the French DisCoVeRy Trial Management Team.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Study protocol and statistical analysis plan will be available from September 2020 with no time limit.&#xD;
Other data will be available upon request after first publication of the results for at least 5 years</ipd_time_frame>
    <ipd_access_criteria>Study protocol and statistical analysis plan will be published. All requests for the trial's data will be considered by the French DisCoVeRy Trial Management Team that can be contacted via the principal investigator: florence.ader@chu-lyon.fr</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

